How MOTS-C Affects HbA1c

MOTS-C influences HbA1c indirectly, through its effect on ambient glucose:

1. Lower average glucose: HbA1c measures the percentage of haemoglobin that has been glycated by glucose over the red cell's lifespan. Anything that lowers average blood glucose, including AMPK-driven glucose uptake, will gradually lower HbA1c.
2. Improved insulin sensitivity: by helping muscle clear glucose with less insulin, MOTS-C reduces the post-meal and fasting glucose excursions that drive glycation (Lee et al., 2015).
3. No direct effect on haemoglobin: MOTS-C does not alter red cell turnover, so it does not produce the false HbA1c readings seen with conditions that change red cell lifespan.

Because HbA1c integrates 90 days of glucose, it lags behind fasting glucose and insulin and should be read as a confirmation of trend, not an early indicator.

Evidence caveat: the link between MOTS-C and HbA1c in humans is observational. No interventional trial has shown native MOTS-C lowers HbA1c in healthy athletes.

Observational human data:

• Lower endogenous MOTS-C correlates with worse glycemic control, and circulating MOTS-C is lower in patients with inadequately controlled type 2 diabetes (HbA1c above 7%)
• In obese youth, MOTS-C correlated inversely with HbA1c (Du et al., 2018)

Plausible direction:

• In a metabolically healthy athlete with a normal baseline HbA1c (below 5.4%), expect little visible movement; there is not much room to improve
• The realistic goal for most enhanced athletes is to keep HbA1c from creeping up during a GH-secretagogue or AAS cycle, rather than to drive it down

The threshold that matters: HbA1c climbing above 5.7% (prediabetes range) during an MK-677 or GH bulk is a warning sign. Most bodybuilding panels omit HbA1c entirely, which is a mistake for anyone running compounds that stress glucose.

Timing: HbA1c at baseline and again at week 12. Testing it more often than every 8-12 weeks is wasteful because it moves slowly.

Read it as confirmation: use fasting glucose and HOMA-IR for your early reads at week 4 and 8, then use HbA1c at week 12 to confirm whether the trend held over the full quarter.

Stable is a win: if you are running MOTS-C alongside compounds that push glucose up, an HbA1c that holds flat across 12 weeks is a meaningful result, not a null one.

Confounders: anything that shortens red cell lifespan (recent blood donation, haemolysis, iron-deficiency correction) can distort HbA1c. Interpret alongside the rest of the metabolic panel.

Add HbA1c to your panel: the single most useful action here is simply including HbA1c at all, since most enhanced-athlete bloodwork skips it. It is the best slow-integrating check on whether your glucose control is drifting.

If HbA1c climbs despite MOTS-C: look hard at what else changed, usually a GH secretagogue on the stack or a large carbohydrate surplus. MOTS-C is not powerful enough to override aggressive metabolic stressors.

Pair with the better-evidenced levers: dietary carbohydrate management, zone 2 cardio, and metformin or berberine all have stronger HbA1c track records than MOTS-C.

Confirm persistence: if HbA1c improves, retest four weeks after the cycle to see whether the gain holds once the peptide is stopped.